HTA59 Anticipating Market Access Challenges in Canada for Lecanemab: Learnings from Previous Health Technology Assessments of Disease-Modifying Therapies in Neurodegenerative Diseases
Abstract
Authors
J. Sosa L. Perez-Kempner D. Stan